济南睾丸是怎么回事呢(济南阳痿一般怎么调理) (今日更新中)

The deaths of 22 more children from flu-related causes were reported Friday by the US Centers for Disease Control and Prevention in its weekly surveillance report.Those deaths bring the total number of children reported to have died to 84 since October, when the current flu season began. Three out of four children who died from the flu had not gotten a flu vaccine, the acting director of the CDC said in a Thursday news conference. "We continue to recommend parents get their children vaccinated even though it's late in the season," Dr. Anne Schuchat said. The season may continue for several more weeks, she added.  633

The caravan of Central American migrants going through Mexico to the US border isn't ending. Instead, its participants will disperse into smaller groups after reaching Mexico City.While some will stay in Mexico to try to get refugee status there, others will continue north to the US border.Organizers of the caravan estimate that some 200 or so people will proceed all the way to the US border in the coming days, although the number could be higher. Last year, about 150 went all the way to the border, they said. 523

The Detroit Lions have issued a statement in response to reports coach Matt Patricia was indicted on sex assault in a case that was ultimately dismissed.Court records for Cameron County, Texas show Patricia and Gregory Dietrich were indicted in August 1996 on sex assault charges.The case was dismissed in January 1997.The Lions have released the following statements from Matt Patricia and from Lions' owner Martha Firestone Ford, Bob Quinn and Rod Wood.Matt Patricia: 482

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The Centers for Disease Control and Prevention is asking people who take a COVID-19 vaccine to download a smartphone app so it can continue to track side effects.The app, called V-Safe, uses text messages and web surveys from the CDC to check in with patients who have gotten a COVID-19 vaccine.The app will also remind patients when it's time to go back for a second shot.Patients can expect to experience mild symptoms like fever, headache and muscle aches after taking the vaccine. But doctors, like Dr. Grace Lee — the associate chief medical officer for practice innovation at Stanford Children's Health and a member of the CDC's vaccine advisory panel — say those side effects don't tend to last very long."We hope that patients will be willing to engage in the system, recognizing it does take some time," Lee said. "But it's really important for all of us in the U.S. to make sure that we are helping to create a robust vaccine safety monitoring system for all COVID vaccines."Lee says that because clinical trials for COVID-19 vaccines have been so large — with 30,000 to 60,000 people in each trial, compared to just several thousand for a typical trial — there's already a lot known about the vaccines.The trials have shown no major safety risks thus far, but Lee says rare adverse events can happen — like the two healthcare workers in Alaska earlier this week who suffered anaphylactic allergic reactions with the Pfizer vaccine. The side effects reported by those two patients were similar to the ones suffered by two people in the U.K. earlier this month.Lee says that's why the CDC is counting on as many people as possible to use V-Safe."My hope is that if the numbers are high," Lee said. "It just means it gives us more information more quickly, and so for anything rare that might occur, we would be able to pick it up much more quickly."V-Safe send text messages to patients, asking them how they are feeling for up to six weeks after their shots. The CDC says the questions take less than five minutes to answer and that the information patients provide will be confidential and private. 2117

来源：资阳报